Published in Hum Gene Ther on May 01, 2008
Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol (2009) 3.06
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther (2009) 1.44
An efficient low cost method for gene transfer to T lymphocytes. PLoS One (2013) 0.95
Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. J Immunol Methods (2013) 0.85
A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices (2010) 0.83
Single-step electrical field strength screening to determine electroporation induced transmembrane transport parameters. Biochim Biophys Acta (2016) 0.76
Artificial MicroRNAs as Novel Secreted Reporters for Cell Monitoring in Living Subjects. PLoS One (2016) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood (1998) 6.26
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol (2005) 3.15
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A (2004) 2.70
Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther (2006) 2.34
Role of chemokines in the biology of natural killer cells. J Leukoc Biol (2002) 2.34
Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature (1996) 2.14
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther (2005) 2.04
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol (1995) 1.91
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother (2005) 1.91
Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther (2006) 1.83
Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol (1997) 1.78
Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol (1999) 1.73
Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res (1992) 1.51
Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol (2005) 1.36
Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma (2005) 1.30
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol (2003) 1.30
Synergy between tumor immunotherapy and antiangiogenic therapy. Blood (2003) 1.23
Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype. Clin Exp Metastasis (2004) 1.22
A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother (2005) 1.11
Antigen-specific cellular immunotherapy of leukemia. Leukemia (2005) 1.08
Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol (2004) 1.04
Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 gamma chemoattractant for human neutrophils and dendritic cells. J Immunol (2000) 1.03
Fatal attraction: cytomegalovirus-encoded chemokine homologs. Curr Top Microbiol Immunol (2002) 1.02
Sequence variability of the alpha-chemokine UL146 from clinical strains of human cytomegalovirus. J Med Virol (2004) 1.02
Retroviral gene therapy: safety issues and possible solutions. Curr Gene Ther (2005) 1.00
CXCR2--the receptor to hit? Drug News Perspect (2006) 0.99
Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. Blood (2003) 0.96
The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells. Carcinogenesis (2005) 0.93
Characterization of GRO alpha, beta and gamma expression in human colonic tumours: potential significance of cytokine involvement. Surg Oncol (1992) 0.90
Current status of genetic modification of T cells for cancer treatment. Cytotherapy (2005) 0.88
Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. J Immunother (2006) 0.87
Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model. Immunol Rev (2001) 0.86
T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production. Int Immunol (2006) 0.85
Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol (2006) 0.85
Trafficking of activated cytotoxic T lymphocytes into the central nervous system: use of a transgenic model. J Neuroimmunol (1993) 0.81
Adoptive immunotherapy for interstitial pneumonia associated with cytomegalovirus infection. Clin Infect Dis (1997) 0.78
Immunotherapy with virus-specific cytotoxic T lymphocytes after organ transplantation. Pediatr Transplant (2006) 0.77
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2007) 2.99
Impact of PhD training on scholarship in a neurosurgical career. J Neurosurg (2013) 2.59
Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood (2003) 2.31
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res (2002) 2.23
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery (2012) 2.19
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
Proteomic and immunologic analyses of brain tumor exosomes. FASEB J (2008) 2.11
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol (2005) 1.85
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res (2003) 1.85
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res (2008) 1.80
Phospholipase C and protein kinase A mediate bradykinin sensitization of TRPA1: a molecular mechanism of inflammatory pain. Brain (2008) 1.78
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol (2009) 1.65
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res (2011) 1.64
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2005) 1.63
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res (2006) 1.63
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res (2006) 1.62
Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus (2006) 1.61
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood (2011) 1.54
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol (2009) 1.53
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood (2007) 1.49
Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther (2011) 1.45
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A (2012) 1.44
Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol (2011) 1.42
EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol (2007) 1.38
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer (2009) 1.35
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res (2004) 1.33
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther (2009) 1.29
Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood (2004) 1.29
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol (2011) 1.29
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res (2002) 1.27
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery (2007) 1.27
Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol (2004) 1.23
Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors. Radiology (2006) 1.23
Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery (2002) 1.23
Immunotherapy of malignant brain tumors. Immunol Rev (2008) 1.20
Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods (2008) 1.19
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw (2011) 1.16
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer (2011) 1.16
Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res (2006) 1.15
Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients. Neurosurgery (2005) 1.14
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2011) 1.13
Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Invest (2014) 1.11
Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neurooncol (2009) 1.11
Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys (2013) 1.11
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol (2010) 1.10
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol (2007) 1.10
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Low-grade glioma. J Neurosurg (2010) 1.08
Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. Int J Radiat Oncol Biol Phys (2008) 1.07
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One (2013) 1.07
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol (2010) 1.06
Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev (2012) 1.06
Oncolytic polio virotherapy of cancer. Cancer (2014) 1.05
Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res (2004) 1.05
A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol (2010) 1.04
Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep (2010) 1.04
Growth hormone accelerates immune recovery following allogeneic T-cell-depleted bone marrow transplantation in mice. Exp Hematol (2003) 1.01
Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics (2009) 1.00
The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am (2010) 0.98
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol (2011) 0.98
A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One (2011) 0.98
Monitoring radiographic brain tumor progression. Toxins (Basel) (2011) 0.98
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol (2013) 0.97
Response to auxin changes during maturation-related loss of adventitious rooting competence in loblolly pine (Pinus taeda) stem cuttings. Physiol Plant (2001) 0.97
The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol (2003) 0.96
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother (2015) 0.95
Deficiencies in pro-thyrotropin-releasing hormone processing and abnormalities in thermoregulation in Cpefat/fat mice. J Biol Chem (2002) 0.95
Contemporary surgical management of vestibular schwannomas: analysis of complications and lessons learned over the past decade. Neurosurgery (2013) 0.95
Frequency-dependent ERK phosphorylation in spinal neurons by electric stimulation of the sciatic nerve and the role in electrophysiological activity. Mol Pain (2007) 0.94
Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model. Transplantation (2002) 0.92
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother (2013) 0.92
EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunol Immunother (2007) 0.92
Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus (2006) 0.91
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol (2004) 0.91
A comparison of murine T-cell-depleted adult bone marrow and full-term fetal blood cells in hematopoietic engraftment and immune reconstitution. Blood (2002) 0.91
Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol (2012) 0.91
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. Nucl Med Biol (2009) 0.91
Paraganglioma of the head and neck: long-term local control with radiotherapy. Am J Clin Oncol (2009) 0.91
Vascular endothelial cells produce soluble factors that mediate the recovery of human hematopoietic stem cells after radiation injury. Biol Blood Marrow Transplant (2006) 0.90
Imaging of convection enhanced delivery of toxins in humans. Toxins (Basel) (2011) 0.90
Regulation of gonadotropin-releasing hormone secretion by cannabinoids. Endocrinology (2005) 0.90
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol (2012) 0.89